drugset
drugset / Trial / NCT04907019

A Drug Interaction Study of SY-004 Capsules in Healthy Subjects

NCT04907019 ↗

Phase 1 Completed 24 enrolled Suzhou Yabao Pharmaceutical R&D Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

A single center, open-label, single sequence study was conducted to evaluate the potential drug interaction of CYP3A4 inducer rifampicin with SY-004 capsules in healthy subjects

Timeline

Start
2021-07-06
Primary completion
2021-08-17
Completion
2021-08-17

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2608204 Small molecule 80 mg Oral
Subject Rifampin Small molecule 600 mg Oral

Indications

type 2 diabetes mellitus